Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Giovanni Manfredi Assanto, Emilia Scalzulli, Ida Carmosino, Maurizio Martelli & Massimo Breccia. (2022) From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care. Expert Review of Hematology 15:11, pages 963-971.
Read now
Read now
Jessica K. Altman, Amy K. Szilard & Leonidas C. Platanias. (2013) Tyrosine kinase inhibition in acute myeloid leukemia. Leukemia & Lymphoma 54:7, pages 1351-1352.
Read now
Read now
Jessica K. Altman & Leonidas C. Platanias. (2012) A new purpose for an old drug: inhibiting autophagy with clarithromycin. Leukemia & Lymphoma 53:7, pages 1255-1256.
Read now
Read now
Ryan D Gentzler, Jessica K Altman & Leonidas C Platanias. (2012) An overview of the mTOR pathway as a target in cancer therapy. Expert Opinion on Therapeutic Targets 16:5, pages 481-489.
Read now
Read now
Articles from other publishers (34)
Erfan Zaker, Negar Nouri, Sepehr Sorkhizadeh, Hamidreza Ghasemirad, Amir Hossein Hajijafari & Fateme Zare. (2023) The importance of personalized medicine in chronic myeloid leukemia management: a narrative review. Egyptian Journal of Medical Human Genetics 24:1.
Crossref
Crossref
Negar Nouri, Valiollah Mehrzad, Zahra Khalaj, Erfan Zaker, Fateme Zare, Elham Abbasi, Maede Khosravi, Seyed Mehdi Kalantar & Mansoor Salehi. (2023) Effects of ABCG2 C421A and ABCG2 G34A genetic polymorphisms on clinical outcome and response to imatinib mesylate, in Iranian chronic myeloid leukemia patients. Egyptian Journal of Medical Human Genetics 24:1.
Crossref
Crossref
Kittappa Vinothkumar, Sayantan Chanda, Vivek Kumar Singh, Sutapa Biswas, Sonali Mohapatra, Ghanashyam Biswas & Soumen Chakraborty. (2022) EVI1 upregulates PTGS1 (COX1) and decreases the action of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia cells. International Journal of Hematology 117:1, pages 110-120.
Crossref
Crossref
Raquel Alves, Ana Cristina Gonçalves, Sergio Rutella, António M. Almeida, Javier De Las Rivas, Ioannis P. Trougakos & Ana Bela Sarmento Ribeiro. (2021) Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance. Cancers 13:19, pages 4820.
Crossref
Crossref
J. Sumalatha, A. Sreedevi & C. Radha Rani. (2020) An Efficient and Green Synthesis of Fluorine Containing
Benzo[a]xanthen-11(12H)-ones and Evaluation of their Anticancer Activity. Asian Journal of Chemistry 32:4, pages 923-929.
Crossref
Crossref
Jing Zeng, Hua lin Cai, Zhi ping Jiang, Qing Wang, Yan Zhu, Ping Xu & Xie lan Zhao. (2017) A validated UPLC–MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. Journal of Pharmaceutical Analysis 7:6, pages 374-380.
Crossref
Crossref
Loredana Salerno, Giuseppe Romeo, Maria N. Modica, Emanuele Amata, Valeria Sorrenti, Ignazio Barbagallo & Valeria Pittalà. (2017) Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia. European Journal of Medicinal Chemistry 142, pages 163-178.
Crossref
Crossref
Sócrates Avilés-Vázquez, Antonieta Chávez-González, Alfredo Hidalgo-Miranda, Dafne Moreno-Lorenzana, Lourdes Arriaga-Pizano, Miguel Á. Sandoval-Esquivel, Manuel Ayala-Sánchez, Rafael Aguilar, Luis Alfaro-Ruiz & Hector Mayani. (2017) Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib. Cancer Medicine 6:12, pages 2942-2956.
Crossref
Crossref
Mohamed A. M. Ali. (2016) Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy. Molecular Diagnosis & Therapy 20:4, pages 315-333.
Crossref
Crossref
Chunming Gu, Maoxiao Feng, Zhao Yin, Xiaochuang Luo, Juhua Yang, Yumin Li, Tianfu Li, Ruirui Wang & Jia Fei. (2016) RalA, a GTPase targeted by miR-181a, promotes transformation and progression by activating the Ras-related signaling pathway in chronic myelogenous leukemia. Oncotarget 7:15, pages 20561-20573.
Crossref
Crossref
Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, Juri Sakuta & Kazuma Ohyashiki. (2015) Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells. Oncotarget 6:24, pages 20231-20240.
Crossref
Crossref
Q Zheng, H Wu, Q Yu, D H Kim, J H Lipton, S Angelini, S Soverini, D Vivona, N Takahashi & J Cao. (2014) ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis. The Pharmacogenomics Journal 15:2, pages 127-134.
Crossref
Crossref
Branimir I. Sikic. 2015. The Molecular Basis of Cancer. The Molecular Basis of Cancer
651
660.e4
.
Debora A. Casolari & Junia V. Melo. 2015. Chromosomal Translocations and Genome Rearrangements in Cancer. Chromosomal Translocations and Genome Rearrangements in Cancer
107
138
.
James W. Mier, Rupal S. Bhatt, David J. Panka & Michael B. Atkins. 2015. Renal Cell Carcinoma. Renal Cell Carcinoma
319
348
.
Kendra Sweet, Najla H. Al Ali, Samir M. Dalia, Rami S. Komrokji, Robert M. Crescentini, Sara Tinsley, Jeffrey E. Lancet, Peter R. Papenhausen, Ling Zhang & Javier Pinilla-Ibarz. (2014) Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia. International Journal of Hematology 100:6, pages 567-574.
Crossref
Crossref
Carlo Gambacorti‐Passerini, Tim H. Brümmendorf, Dong‐Wook Kim, Anna G. Turkina, Tamas Masszi, Sarit Assouline, Simon Durrant, Hagop M. Kantarjian, H. Jean Khoury, Andrey Zaritskey, Zhi‐Xiang Shen, Jie Jin, Edo Vellenga, Ricardo Pasquini, Vikram Mathews, Francisco Cervantes, Nadine Besson, Kathleen Turnbull, Eric Leip, Virginia Kelly & Jorge E. Cortes. (2014) Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24‐month follow‐up. American Journal of Hematology 89:7, pages 732-742.
Crossref
Crossref
Stefan Balabanov, Melanie Braig & Tim H. Br?mmendorf. (2014) Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia. Drug Discovery Today: Technologies 11, pages 89-99.
Crossref
Crossref
Luciene Terezina de Lima, Douglas Vivona, Carolina Tosin Bueno, Rosario D. C. Hirata, Mario H. Hirata, André D. Luchessi, Fabíola Attié de Castro, Maria de Lourdes F. Chauffaille, Maria A. Zanichelli, Carlos S. Chiattone, Vania T. M. Hungria & Elvira M. Guerra-Shinohara. (2014) Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. Medical Oncology 31:3.
Crossref
Crossref
Markus D. Herrmann, Jochen K. Lennerz, Lars Bullinger, Stephan Bartholomae, Karlheinz Holzmann, Mike-Andrew Westhoff, Selim Corbacioglu & Klaus-Michael Debatin. (2014) Transitory dasatinib-resistant states in KITmut t(8;21) acute myeloid leukemia cells correlate with altered KIT expression. Experimental Hematology 42:2, pages 90-100.
Crossref
Crossref
Richard D. Press, Suzanne Kamel-Reid & Daphne Ang. (2013) BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. The Journal of Molecular Diagnostics 15:5, pages 565-576.
Crossref
Crossref
Sunwen Chou, Ronald J. Ercolani, Gail Marousek & Terry L. Bowlin. (2013) Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance. Antimicrobial Agents and Chemotherapy 57:7, pages 3375-3379.
Crossref
Crossref
Massimo Breccia & Giuliana Alimena. (2013) The role of comorbidities in chronic myeloid leukemia. Leukemia Research 37:7, pages 729-730.
Crossref
Crossref
Tomasz Stoklosa, Eliza Glodkowska-Mrowka, Grazyna Hoser, Magdalena Kielak, Ilona Seferynska & Pawel Wlodarski. (2013) Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia. Experimental Hematology 41:5, pages 462-469.
Crossref
Crossref
S.J. Seong, M. Lim, S.K. Sohn, J.H. Moon, S.-J. Oh, B.S. Kim, H.M. Ryoo, J.S. Chung, Y.D. Joo, S.M. Bang, C.W. Jung, D.H. Kim, S.Y. Park, S.S. Yoon, I. Kim, H.G. Lee, J.H. Won, Y.H. Min, J.W. Cheong, J.S. Park, K.S. Eom, M.S. Hyun, M.K. Kim, H. Kim, M.R. Park, J. Park, C.S. Kim, H.J. Kim, Y.K. Kim, E.K. Park, D.Y. Zang, D.Y. Jo, H.W. Lee & Y.-R. Yoon. (2013) Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Annals of Oncology 24:3, pages 756-760.
Crossref
Crossref
CHANG-CHUN NIU, CHEN ZHAO, ZHEN-DONG YANG, XIAO-LI ZHANG, WEI-RU WU, JING PAN, CHEN ZHAO, ZHI-QIANG LI, WEI DING, ZHONG YANG & WEI-KE SI. (2013) Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition. International Journal of Molecular Medicine 31:2, pages 453-458.
Crossref
Crossref
Seonyang Park, Youngil Koh, Seung-Hyun Jung & Yeun-Jun Chung. 2013. Array Comparative Genomic Hybridization. Array Comparative Genomic Hybridization
55
68
.
Kazuyuki Shimada, Akihiro Tomita, Yosuke Minami, Akihiro Abe, Charlotte K. Hind, Hitoshi Kiyoi, Mark S. Cragg & Tomoki Naoe. (2012) CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737. Experimental Hematology 40:9, pages 724-737.e2.
Crossref
Crossref
Matthew M. Seavey & Pawel Dobrzanski. (2012) The many faces of Janus kinase. Biochemical Pharmacology 83:9, pages 1136-1145.
Crossref
Crossref
James W. Mier. 2012. Renal Cell Carcinoma. Renal Cell Carcinoma
283
303
.
Eliza Vakana & Leonidas C. Platanias. (2011) AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget 2:12, pages 1322-1328.
Crossref
Crossref
Baisong Liao, Yan Hu & Gary Brewer. (2011) RNA-binding Protein Insulin-like Growth Factor mRNA-binding Protein 3 (IMP-3) Promotes Cell Survival via Insulin-like Growth Factor II Signaling after Ionizing Radiation. Journal of Biological Chemistry 286:36, pages 31145-31152.
Crossref
Crossref
Tariq I. Mughal, Jerald P. Radich, Richard A. Van Etten, Alfonso Quintás‐Cardama, Tomasz Skorski, Farhad Ravandi, Daniel J. DeAngelo, Carlo Gambacorti‐Passerini, Giovanni Martinelli & Ayalew Tefferi. (2011) Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR‐ABL1 positive and BCR‐ABL1 negative myeloproliferative neoplasms workshop. American Journal of Hematology 86:9, pages 811-819.
Crossref
Crossref
Marie P. ShiehMasato MitsuhashiMichael Lilly. (2011) Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML. Clinical Medicine Insights: Oncology 5, pages CMO.S6416.
Crossref
Crossref